Hengrui Pharma(SH:600276) Ge Long Hui·2025-12-19 10:25Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, marking a significant step in its drug development pipeline [1] Group 1: SHR-9539 Injection - SHR-9539 injection is a Class 1 therapeutic biological product that targets and kills multiple myeloma cells by activating T cells [1] - Currently, there are no similar drugs approved for market in China [1] - The cumulative R&D investment for the SHR-9539 injection project is approximately 39.93 million yuan [1] Group 2: HRS-3738 Tablets - HRS-3738 tablets are a next-generation CRBN E3 ubiquitin ligase modulator that affects the proliferation of hematological tumor cells by degrading specific substrates [1] - The drug has potential advantages in substrate degradation capability and overcoming drug resistance [1] - There are no similar drugs approved for market domestically or internationally [1] - The cumulative R&D investment for the HRS-3738 tablet project is approximately 63.63 million yuan [1]